S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33

ANI Pharmaceuticals Stock Forecast, Price & News

+0.15 (+0.47 %)
(As of 09/24/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume87,978 shs
Average Volume58,979 shs
Market Capitalization$407.75 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ANIP News and Ratings via Email

Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ANI Pharmaceuticals logo

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc. is a pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.33 out of 5 stars

Medical Sector

225th out of 1,351 stocks

Pharmaceutical Preparations Industry

104th out of 664 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

ANI Pharmaceuticals (NASDAQ:ANIP) Frequently Asked Questions

Is ANI Pharmaceuticals a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANI Pharmaceuticals stock.
View analyst ratings for ANI Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than ANI Pharmaceuticals?

Wall Street analysts have given ANI Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ANI Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is ANI Pharmaceuticals' next earnings date?

ANI Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for ANI Pharmaceuticals

How were ANI Pharmaceuticals' earnings last quarter?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) announced its earnings results on Thursday, August, 5th. The specialty pharmaceutical company reported $0.67 earnings per share for the quarter, topping analysts' consensus estimates of $0.51 by $0.16. ANI Pharmaceuticals had a negative net margin of 8.07% and a positive trailing twelve-month return on equity of 17.57%. During the same period in the prior year, the firm earned $0.69 earnings per share.
View ANI Pharmaceuticals' earnings history

How has ANI Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

ANI Pharmaceuticals' stock was trading at $38.30 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ANIP stock has decreased by 16.6% and is now trading at $31.95.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ANIP?

1 analysts have issued 12-month target prices for ANI Pharmaceuticals' stock. Their forecasts range from $60.00 to $60.00. On average, they expect ANI Pharmaceuticals' share price to reach $60.00 in the next year. This suggests a possible upside of 87.8% from the stock's current price.
View analysts' price targets for ANI Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are ANI Pharmaceuticals' key executives?

ANI Pharmaceuticals' management team includes the following people:
  • Nikhil Lalwani, President, Chief Executive Officer & Director
  • James G. Marken, Senior VP-Operations & Product Development
  • Stephen P. Carey, Chief Financial Officer, Secretary & VP
  • Rob W. Schrepfer, SVP-New Business Development & Specialty Sales
  • Christopher K. Mutz, Chief Commercial Officer & Head-Rare Diseases

What is Arthur Przbyl's approval rating as ANI Pharmaceuticals' CEO?

1 employees have rated ANI Pharmaceuticals CEO Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among ANI Pharmaceuticals' employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ANI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC).

What is ANI Pharmaceuticals' stock symbol?

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

Who are ANI Pharmaceuticals' major shareholders?

ANI Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.50%), Vanguard Group Inc. (5.01%), Dimensional Fund Advisors LP (3.55%), State Street Corp (3.13%), Thompson Siegel & Walmsley LLC (3.08%) and Goldman Sachs Group Inc. (2.83%). Company insiders that own ANI Pharmaceuticals stock include Patrick D Walsh and Thomas Haughey.
View institutional ownership trends for ANI Pharmaceuticals

Which major investors are selling ANI Pharmaceuticals stock?

ANIP stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Russell Investments Group Ltd., Renaissance Technologies LLC, Vanguard Group Inc., Prudential Financial Inc., Victory Capital Management Inc., Bank of New York Mellon Corp, and Legal & General Group Plc.
View insider buying and selling activity for ANI Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying ANI Pharmaceuticals stock?

ANIP stock was purchased by a variety of institutional investors in the last quarter, including Thompson Siegel & Walmsley LLC, Dimensional Fund Advisors LP, Goldman Sachs Group Inc., GSA Capital Partners LLP, First Wilshire Securities Management Inc., Deutsche Bank AG, Geode Capital Management LLC, and Public Sector Pension Investment Board. Company insiders that have bought ANI Pharmaceuticals stock in the last two years include Patrick D Walsh, and Thomas Haughey.
View insider buying and selling activity for ANI Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of ANI Pharmaceuticals?

Shares of ANIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ANI Pharmaceuticals' stock price today?

One share of ANIP stock can currently be purchased for approximately $31.95.

How much money does ANI Pharmaceuticals make?

ANI Pharmaceuticals has a market capitalization of $407.75 million and generates $208.48 million in revenue each year. The specialty pharmaceutical company earns $-22,550,000.00 in net income (profit) each year or $2.87 on an earnings per share basis.

How many employees does ANI Pharmaceuticals have?

ANI Pharmaceuticals employs 369 workers across the globe.

What is ANI Pharmaceuticals' official website?

The official website for ANI Pharmaceuticals is www.anipharmaceuticals.com.

Where are ANI Pharmaceuticals' headquarters?

ANI Pharmaceuticals is headquartered at 210 Main Street West, Baudette MN, 56623.

How can I contact ANI Pharmaceuticals?

ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company can be reached via phone at (218) 634-3500 or via email at [email protected].

This page was last updated on 9/25/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.